The US is increasingly becoming attractive again to IP-rich companies, especially large US pharmaceuticals and technology multinationals. Deductions from foreign-derived income attributable to intangibles (FDII) serve as a carrot, but other provisions in the tax code may yet impact the cost of relocating assets.